Spoken Alpha
Zomedica Corp.
Zomedica designs and manufactures diagnostic and therapeutic medical devices for companion animals, including dogs, cats, and horses.
Zomedica Corp is a Healthcare company operating in Medical Devices with a $87.2M market cap.
Most recent earnings call: Q4 FY24 on Mar 13, 2025.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-06-21.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Reported quarters with consensus, surprise, and 1-day reaction context.
Spoken Alpha tracks ZOMDF's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Misses consensus 7/10 quarters
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for ZOMDF.
$ curl https://api.spokenalpha.com/v1/companies/ZOMDFFAQ
Spoken Alpha indexes ZOMDF's earnings call transcripts at https://spokenalpha.com/companies/ZOMDF. Each call links to attributed speakers and parsed analyst Q&A. Zomedica Corp.'s own investor relations page is at https://investors.zomedica.com/.
Zomedica Corp. (ZOMDF) held its most recent earnings call on 2025-03-13, covering fiscal Q4 2024.
Zomedica Corp. (ZOMDF) operates in the Healthcare sector (Medical Devices industry).
Repeated misses without a guidance reset suggest management is structurally optimistic relative to operating reality. Track whether next-quarter guidance is being benchmarked off the prior miss or the prior plan.
Missed in 2 of the last 4 quarters
SampleRecent misses matter more than long-window beat rate — the trailing 12 months drives the analyst model and the next-print bar.
| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2024 | $2.62 | $2.51 | +4.5% | +2.4% | +5.1% |
| Q4 FY2024 | $2.63 | $2.64 | -0.3% | -0.8% | +2.1% |
| Q3 FY2024 | $2.27 | $2.50 | -9.0% | +7.6% | +8.0% |
| Q2 FY2024 | $2.61 | $2.59 | +0.9% | -3.4% | -6.3% |
| Q1 FY2023 | $2.54 | $2.50 | +1.7% | +7.5% | +8.0% |
COO since 2025 • 1/2 beats (50%) • last guidance raise Q1 FY2024
| Q4 FY2023 |
| $2.24 |
| $2.47 |
| -9.5% |
| +5.9% |
| +8.3% |
| Q3 FY2023 | $2.43 | $2.62 | -7.1% | +3.6% | +5.8% |
| Q2 FY2023 | $2.65 | $2.77 | -4.5% | +6.7% | +6.3% |
| Q1 FY2022 | $2.48 | $2.51 | -1.2% | -1.7% | -2.9% |
| Q4 FY2022 | $2.51 | $2.65 | -5.3% | +8.2% | +8.5% |